Masquelier M - Search Results

1

Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9.

Helldén A, Bergman U, Engström Hellgren K, Masquelier M, Nilsson Remahl I, Odar-Cederlöf I, Ramsjö M, Bertilsson L. Helldén A, et al. Among authors: masquelier m. Eur J Clin Pharmacol. 2010 Aug;66(8):791-5. doi: 10.1007/s00228-010-0820-7. Epub 2010 Apr 20. Eur J Clin Pharmacol. 2010. PMID: 20405111

2

Clinically significant CYP2C inhibition by noscapine but not by glucosamine.

Rosenborg S, Stenberg M, Otto S, Ostervall J, Masquelier M, Yue QY, Bertilsson L, Eliasson E. Rosenborg S, et al. Among authors: masquelier m. Clin Pharmacol Ther. 2010 Sep;88(3):343-6. doi: 10.1038/clpt.2010.107. Epub 2010 Jul 28. Clin Pharmacol Ther. 2010. PMID: 20668444 Clinical Trial.

3

Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response.

Bogason A, Bhuiyan H, Masquelier M, Paul C, Gruber A, Vitols S. Bogason A, et al. Among authors: masquelier m. Eur J Clin Pharmacol. 2009 Dec;65(12):1179-86. doi: 10.1007/s00228-009-0734-4. Epub 2009 Oct 10. Eur J Clin Pharmacol. 2009. PMID: 19820921

4

Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.

Bogason A, Quartino AL, Lafolie P, Masquelier M, Karlsson MO, Paul C, Gruber A, Vitols S. Bogason A, et al. Among authors: masquelier m. Br J Clin Pharmacol. 2011 Apr;71(4):514-21. doi: 10.1111/j.1365-2125.2010.03894.x. Br J Clin Pharmacol. 2011. PMID: 21204910 Free PMC article.

5

Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside.

Masquelier M, Vitols S. Masquelier M, et al. Biochem Pharmacol. 2004 May 1;67(9):1639-46. doi: 10.1016/j.bcp.2003.12.034. Biochem Pharmacol. 2004. PMID: 15081863

6

Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines.

Tatidis L, Masquelier M, Vitols S. Tatidis L, et al. Among authors: masquelier m. Biochem Pharmacol. 2002 Jun 15;63(12):2169-80. doi: 10.1016/s0006-2952(02)01018-3. Biochem Pharmacol. 2002. PMID: 12110376

7

Relationship between daunorubicin concentration and apoptosis induction in leukemic cells.

Masquelier M, Zhou QF, Gruber A, Vitols S. Masquelier M, et al. Biochem Pharmacol. 2004 Mar 15;67(6):1047-56. doi: 10.1016/j.bcp.2003.10.025. Biochem Pharmacol. 2004. PMID: 15006541

8

Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia.

Bogason A, Masquelier M, Lafolie P, Skogastierna C, Paul C, Gruber A, Vitols S. Bogason A, et al. Among authors: masquelier m. Drug Metab Lett. 2010 Dec;4(4):228-32. doi: 10.2174/187231210792928260. Drug Metab Lett. 2010. PMID: 20670211

9

Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins.

Masquelier M, Tirzitis G, Peterson CO, Pålsson M, Amolins A, Plotniece M, Plotniece A, Makarova N, Vitols SG. Masquelier M, et al. Eur J Med Chem. 2000 Apr;35(4):429-38. doi: 10.1016/s0223-5234(00)00139-2. Eur J Med Chem. 2000. PMID: 10858603

10

Quantification of valproic acid in dried blood spots.

Pohanka A, Mahindi M, Masquelier M, Gustafsson LL, Beck O. Pohanka A, et al. Among authors: masquelier m. Scand J Clin Lab Invest. 2014 Oct;74(7):648-52. doi: 10.3109/00365513.2014.933360. Epub 2014 Jul 25. Scand J Clin Lab Invest. 2014. PMID: 25059925

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters